Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 191

Similar articles for PubMed (Select 10092645)

1.
2.
3.
4.
5.

The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.

van den Akker E, van Dijk TB, Schmidt U, Felida L, Beug H, Löwenberg B, von Lindern M.

Biol Chem. 2004 May;385(5):409-13.

PMID:
15196000
7.

Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH.

Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.

PMID:
17098432
8.
10.
11.

Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.

Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM.

Clin Cancer Res. 1999 Jun;5(6):1569-82.

12.

Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.

Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM.

Anticancer Drug Des. 1999 Oct;14(5):403-10.

PMID:
10766295
13.

Structure-based design of novel anticancer agents.

Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK.

Curr Cancer Drug Targets. 2001 May;1(1):59-71. Review.

PMID:
12188892
14.

In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.

Tibbles HE, Samuel P, Erbeck D, Mahajan S, Uckun FM.

Arzneimittelforschung. 2004;54(6):330-9.

PMID:
15281619
15.

Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide.

Ghosh S, Uckun FM.

Acta Crystallogr C. 1999 Aug 15;55 ( Pt 8):1364-5.

PMID:
10483706
16.

Bruton's tyrosine kinase as a new therapeutic target.

Uckun FM, Tibbles HE, Vassilev AO.

Anticancer Agents Med Chem. 2007 Nov;7(6):624-32. Review.

PMID:
18045057
17.

Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex.

Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM.

J Biol Chem. 1999 Jan 15;274(3):1646-56.

18.

Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells.

Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C, Uckun FM.

J Biol Chem. 2001 Aug 17;276(33):31216-28. Epub 2001 Jun 18.

19.

Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.

Gilbert C, Levasseur S, Desaulniers P, Dusseault AA, Thibault N, Bourgoin SG, Naccache PH.

J Immunol. 2003 May 15;170(10):5235-43.

20.

Clinical potential of targeting Bruton's tyrosine kinase.

Uckun FM.

Int Rev Immunol. 2008 Jan-Apr;27(1-2):43-69. doi: 10.1080/08830180701784588. Review.

PMID:
18300055
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk